Vinay Sagar Verma Verma

Nano-immunotherapy leverages advanced nanocarrier systems to overcome limitations of conventional immunotherapies, providing precise immune modulation through targeted delivery of antigens, immunomodulators, and genetic material. Lipid-based, polymeric, inorganic, and hybrid nanocarriers enable controlled release, enhanced bioavailability, and site-specific immune activation, optimizing therapeutic efficacy while minimizing systemic toxicity. Pharmaceutical formulation strategies, including particle engineering, surface functionalization, and payload optimization, are critical to enhancing immune targeting and pharmacokinetics. Clinically, nano-immunotherapeutics have demonstrated remarkable success in vaccines, cancer immunotherapy, and genetic disease treatment, exemplified by mRNA-LNP COVID-19 vaccines and liposomal chemotherapies. Despite challenges in manufacturing, stability, and regulatory approval, emerging trends such as AI-driven design, personalized formulations, and integration with gene-editing technologies forecast a future of precision nano-immunotherapy with broad clinical impact.

Theranostic liposomes represent a paradigm shift in precision nanomedicine by integrating therapeutic drug delivery with diagnostic imaging functionality into a single nanocarrier platform. These dual-function systems address long-standing limitations of conventional therapeutics and diagnostics by enabling simultaneous treatment and real-time monitoring of drug biodistribution, tissue accumulation, and therapeutic response. Structurally composed of phospholipid bilayers, liposomes can encapsulate diverse therapeutic agents—from small-molecule chemotherapeutics to macromolecules like proteins and nucleic acids—while co-loading imaging probes including fluorescent dyes, magnetic resonance imaging (MRI) contrast agents, computed tomography (CT) enhancers, and radionuclides for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). Through rational design strategies including size optimization, PEGylation for prolonged circulation, ligand-mediated active targeting, and incorporation of stimuli-responsive lipids, theranostic liposomes achieve enhanced pharmacokinetics, selective tumor or tissue accumulation, and controlled release kinetics. Pharmacokinetically, these systems exploit the enhanced permeability and retention (EPR) effect for passive targeting and receptor-mediated endocytosis for active targeting, while multimodal imaging enables quantitative assessment of drug localization and therapeutic efficacy. Clinical applications span oncology, cardiovascular disease, neurological disorders, and infectious diseases—with theranostic platforms enabling personalized dosing adjustments, early prediction of therapeutic outcomes, and reduction of off-target toxicity. Despite remarkable potential, challenges including formulation stability, batch-to-batch reproducibility, cost-effective scale-up, and complex regulatory requirements demand continued innovation. Future developments emphasize smart, stimuli-responsive systems, artificial intelligence-driven optimization, biodegradable hybrid architectures, and personalized liposomal engineering. Collectively, theranostic liposomes embody the convergence of materials science, molecular pharmacology, and imaging technology—redefining precision medicine by seamlessly integrating diagnosis, therapy, and real-time disease monitoring into adaptive, patient-centric treatment paradigms.

Biodegradable polymers have emerged as essential components in advanced drug delivery systems, enabling controlled, sustained, and site-specific therapeutic release while minimizing systemic toxicity. This comprehensive review covers the design principles, degradation mechanisms, and drug release dynamics of natural and synthetic biodegradable polymers such as PLGA, PCL, chitosan, and alginate. Their adaptability allows fabrication into nanoparticles, microspheres, hydrogels, and scaffolds tailored to various clinical needs, including cancer therapy, vaccine delivery, gene therapy, and tissue engineering. The review discusses hydrolytic and enzymatic degradation processes, surface versus bulk erosion behaviors, and factors influencing polymer degradation and drug release kinetics. Case studies highlight FDA-approved formulations leveraging these polymers for enhanced therapeutic efficacy and patient compliance. Challenges such as variability in degradation rates, formulation stability, manufacturing scale-up, and regulatory hurdles are addressed. Emerging frontiers in smart stimuli-responsive systems, hybrid polymers, AI-driven design, and personalized medicine underscore the future potential of biodegradable polymers as cornerstones of precision and sustainable therapeutics.

Background: Cancer remains one of the leading causes of morbidity and mortality worldwide, with conventional treatment strategies limited by systemic toxicity, therapeutic resistance, and tumor heterogeneity. The emergence of nanotechnology offers innovative solutions to these challenges, enabling targeted drug delivery, controlled release, and theranostic integration.Objective: This review synthesizes recent progress in cancer nanomedicine, highlighting therapeutic platforms, omics-driven personalization, and clinical translation between 2019 and 2024.Methos: We discuss the major classes of therapeutic nanoplatforms including lipid-based systems, polymeric nanocarriers, inorganic nanoparticles, and hybrid or bioinspired designs detailing their mechanisms of action in targeted delivery, photothermal therapy, and multimodal treatment. Advances in genomics, transcriptomics, proteomics, and metabolomics are explored for their role in guiding nanocarrier design, with emphasis on artificial intelligence–enabled multi-omics integration for precision oncology. Clinical trial progress across liver, lung, pancreatic, breast, and brain cancers demonstrates improved tolerability, patient quality of life, and incremental survival gains, though translation remains constrained by tumor heterogeneity, blood–brain barrier penetration, scalability, cost, and regulatory hurdles.Conclusion: Cancer nanomedicine stands at a pivotal juncture advancing beyond incremental improvements to become a cornerstone of precision oncology. By uniting nanoscale engineering, multi-omics, artificial intelligence, and innovative clinical strategies, the field holds the potential to transform cancer therapy in the decade ahead.